Rationale for Anti-TGF-β Antibody Therapy in Oncology

Transforming Growth Factor-β in Cancer Therapy, Volume II ◽

10.1007/978-1-59745-293-9_46 ◽

2008 ◽

pp. 757-774 ◽

Author(s):

Frank J. Hsu ◽

Beverly A. Teicher ◽

John M. McPherson

Keyword(s):

Antibody Therapy

Download Full-text

Abstract #823: Delayed Onset of Central Adrenal Insufficiency with Anti Pd-1 Antibody Therapy

Endocrine Practice ◽

10.1016/s1530-891x(20)44568-9 ◽

2017 ◽

Vol 23 ◽

pp. 174

Author(s):

Carol Ramirez Rojas ◽

Kim Kevin ◽

Karen Earle

Keyword(s):

Adrenal Insufficiency ◽

Antibody Therapy ◽

Delayed Onset ◽

Central Adrenal Insufficiency

Download Full-text

Insulin Needs After CD3-Antibody Therapy in New-Onset Type 1 Diabetes

Yearbook of Endocrinology ◽

10.1016/s0084-3741(08)70289-0 ◽

2006 ◽

Vol 2006 ◽

pp. 67-69

Author(s):

J.L. Leahy

Keyword(s):

Type 1 Diabetes ◽

Antibody Therapy ◽

Download Full-text

Present Status and Perspectives of Antibody Therapy against Cancer

Japanese Journal of Complementary and Alternative Medicine ◽

10.1625/jcam.2.15 ◽

2005 ◽

Vol 2 (1) ◽

pp. 15-21

Author(s):

Masahide KUROKI ◽

Hirotomo SHIBAGUCHI ◽

Motomu KUROKI

Keyword(s):

Present Status ◽

Antibody Therapy

Download Full-text

SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors

Case Medical Research ◽

10.31525/ct1-nct04291079 ◽

2020 ◽

Author(s):

Keyword(s):

Solid Tumors ◽

Locally Advanced ◽

Antibody Therapy

Download Full-text

Faculty Opinions recommendation of Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1011661.181868 ◽

2003 ◽

Author(s):

Thomas Huenig

Keyword(s):

Autoimmune Disease ◽

Costimulatory Molecule ◽

Antibody Therapy

Download Full-text

Faculty Opinions recommendation of Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1026628.325293 ◽

2005 ◽

Author(s):

Mark Atkinson

Keyword(s):

Type 1 Diabetes ◽

Antibody Therapy ◽

Download Full-text

Faculty Opinions recommendation of Targeting intracellular oncoproteins with antibody therapy or vaccination.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.13294042.14653184 ◽

2011 ◽

Author(s):

Michel L Tremblay ◽

Serge Hardy

Keyword(s):

Antibody Therapy

Download Full-text

Faculty Opinions recommendation of Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.4252956.4109054 ◽

2010 ◽

Author(s):

Tadeusz Robak ◽

Krzysztof Jamroziak

Keyword(s):

B Cell ◽

Effector Cell ◽

Antibody Therapy ◽

Type Ii ◽

Cell Cytotoxicity ◽

Immune Effector Cell ◽

Immune Effector ◽

New Type ◽

Cd20 Antibody ◽

Download Full-text

Mechanisms and Refinements of PSCA Directed Antibody Therapy

10.21236/ada426030 ◽

2004 ◽

Author(s):

Robert E. Reiter

Keyword(s):

Antibody Therapy

Download Full-text

A Journey Into the Biotechnology Industry: Valuation of Early-Stage Companies. Allakos’ Case Study and the Monoclonal Antibody Therapy

SSRN Electronic Journal ◽

10.2139/ssrn.3709335 ◽

2020 ◽

Author(s):

Giovanni Nocera ◽

Dennis Marco Montagna ◽

Emanuele Fino ◽

Antonio Amendola

Keyword(s):

Monoclonal Antibody ◽

Early Stage ◽

Antibody Therapy ◽

Biotechnology Industry ◽

Monoclonal Antibody Therapy

Download Full-text